Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Asta Pharma Aktiengesellschaft

Clemens Unger

Hansjorg Eibl

Jurgen Engel

Petra Kaufmann-Kolle

Anneliese Kranich

The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I ##STR1## in which R.sup.1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R.sup.2, R.sup.3 and R.sup.4 denote independently of one another hydrogen, a C.sub.1 -C.sub.5 alkys group, a C.sub.3 -C.sub.6 cycloalkyl group or a C.sub.1 -C.sub.5 hydroxyalkyl group whereby two of the residues R.sup.2, R.sup.3 and R.sup.4 can together form a C.sub.2 -C.sub.5 alkylene group which, if desired, can be substituted with an --O--, --S-- or NR.sup.5 group, in which R.sup.5 is hydrogen, a C.sub.1 -C.sub.5 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group or a C.sub.1 -C.sub.5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.

Process for the production of a pharmaceutical agent for oral or topical

Liposomes with a negative excess charge

The use of alkylphosphoric acid compounds of Formula I

Use of hexadecylphosphocholine for the treatment of psoriasis

Growing community of inventors

Gottingen, Germany

Clemens Unger